« previous next »
Pages: [1]

Author Topic: (Abst.) COVID-19 outcomes in MS: Observational study of early experience from NYU MS Center  (Read 42 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9842
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) COVID-19 outcomes in MS: Observational study of early experience from NYU MS Center
« on: July 11, 2020, 02:27:37 pm »
From PubMed (July 11, 2020)--"COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center":


https://pubmed.ncbi.nlm.nih.gov/32646885/
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20 - 3/16/24.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
1 Replies
136 Views 		Last post October 29, 2016, 06:34:51 am
by agate
2 Replies
203 Views 		Last post June 18, 2017, 04:06:52 pm
by agate
0 Replies
33 Views 		Last post September 15, 2020, 09:05:44 pm
by agate
0 Replies
40 Views 		Last post February 02, 2021, 09:03:30 pm
by agate
0 Replies
41 Views 		Last post August 16, 2021, 09:19:59 pm
by agate